Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects With Unresectable, Locally Advanced or Metastatic Claudin 18.2+ Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects With Unresectable, Locally Advanced or Metastatic Claudin 18.2+ Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TAC01-CLDN18.2 (Primary) ; Clofarabine; Cyclophosphamide; Fludarabine; Paclitaxel
  • Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms TACTIC-3
  • Sponsors Triumvira

Most Recent Events

  • 12 Mar 2025 According to a Triumvira media release, detailed overview of interim findings data from this study will be presented at the 2025 SITC Spring Scientific, Cellular Therapy and Solid Tumors Conference in San Diego, California, from March 12-14, 2025.
  • 14 Feb 2025 Status changed from recruiting to active, no longer recruiting.
  • 27 Jan 2025 According to a Triumvira media release, company presented an abstract consisting updated clinical data from this ongoing Phase I/II TACTIC-3 study investigating the safety and efficacy of autologous TAC-T cells in subjects with Claudin 18.2+ advanced solid tumors at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which was held in San Francisco, California, from January 23-25, 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top